Please login to the form below

Wilson Therapeutics

This page shows the latest Wilson Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Pfizer goes big on gene therapy with $500m facility spend

That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a ... It also took a 15% stake in Vivet Therapeutics and its lead

Latest news

Alexion targets RNAi with $637m Dicerna deal

The new deal adds to others made by Alexion this year, including the $855m acquisition of rare disease company Wilson Therapeutics in April and privately-held autoimmune disease specialists Syntimmune in
Alexion adds to pipeline with $1.2bn Syntimmune buy

In the meantime, however, it’s also been adding to its earlier-stage pipeline and the Syntimmune acquisition comes a few months after it snapped up Swedish biotech Wilson Therapeutics for ... $855m, adding orally-active copper binder WTX-101 in phase
Abingworth raises $315m to expand hunt for promising biotechs

The acquisitions of rare disease specialist Wilson Therapeutics by Alexion for $855m and of IFM Therapeutics – an immuno-oncology player – by Bristol-Myers Squibb for $1.3bn are recent successes for ... Abingworth has shown it is prepared to back
Alexion adds to pipeline rebuild with $855m Wilson buy

$855m offer for rare disease company Wilson Therapeutics. ... Ludwig Hantson, Alexion’s chief executive, said: “The acquisition of Wilson Therapeutics is a strong strategic fit for Alexion given the overlap with our current clinical and commercial
mRNA - message received

Arcturus Therapeutics. thrombopoietin; alpha-1 antitrypsin replacment; cystic fibrosis; iron disorders. Tekmira, Arrowhead. ... Shire. Eukarys. monogenic liver diseases; Wilson disease. Moderna Therapeutics. cancer; cardiovascular disease; infectious

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest appointments

IGEM Therapeutics appoints Dr Tim Wilson as CEO

Wilson has over 28 years’ experience in the life sciences sector, ranging from venture capital and start-ups to investment banking and equity research. ... Wilson has worked for numerous private and public life science companies in the US and Europe at
Therachon strengthens management team

He currently serves as chairman of Asceneuron, Complix and InteRNA, and as a non-executive director at Hansa Medical, Sobi, Wilson Therapeutics and Dutch Top Sector Life Sciences and Health.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Account Manager – Healthcare advertising: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...